Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy

Halle, Briana Rose; Betof Warner, Allison; Zaman, Farzana Y; Haydon, Andrew; Bhave, Prachi; et al; Dimitriou, Florentia

doi:10.1136/jitc-2021-003066

Citations

Citation copied

Halle, B. R., Betof Warner, A., Zaman, F. Y., Haydon, A., Bhave, P., et al, & Dimitriou, F. (2021). Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. Journal for ImmunoTherapy of Cancer, 9(10), e003066. https://doi.org/10.1136/jitc-2021-003066

Abstract

BackgroundImmune checkpoint inhibitors (ICIs) are approved to treat multiple cancers. Retrospective analyses demonstrate acceptable safety of ICIs in most patients with autoimmune disease, although disease exacerbation may occur. Psoriasis vulgaris is a common, immune-mediated disease, and outcomes of ICI treatment in patients with psoriasis are not well described. Thus we sought to define the safety profile and effectiveness of ICIs in patients with pre-existing psoriasis.MethodsIn this retrospective cohort study, patients from eight